Neurometrix Inc  

(Public, NASDAQ:NURO)   Watch this stock  
Find more results for nuro
-0.04 (-2.60%)
After Hours: 1.60 +0.04 (2.67%)
Sep 26, 4:04PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.55 - 1.61
52 week 1.35 - 3.72
Open 1.61
Vol / Avg. 0.00/96,968.00
Mkt cap 8.03M
P/E     -
Div/yield     -
EPS -10.61
Shares 5.12M
Beta 0.76
Inst. own 9%
Oct 20, 2016
Q3 2016 NeuroMetrix Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 12, 2016
NeuroMetrix Inc at Rodman & Renshaw Global Investment Conference
Jul 21, 2016
Q2 2016 NeuroMetrix Inc Earnings Release
Jul 21, 2016
Q2 2016 NeuroMetrix Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -154.70% -125.86%
Operating margin -157.79% -181.87%
EBITD margin - -178.82%
Return on average assets -122.20% -66.97%
Return on average equity -940.78% -264.21%
Employees 48 -
CDP Score - -


1000 Winter St
WALTHAM, MA 02451-1436
United States - Map
+1-781-8909989 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NeuroMetrix, Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company's products consist of a medical device used in conjunction with a consumable electrode or biosensor. Its products include Quell, which is a wearable device for relief of chronic intractable pain; SENSUS, which is a prescription neuro-stimulation device; DPNCheck, which is a nerve conduction test that is used to evaluate systemic neuropathies, and ADVANCE System, which is a platform for the performance of nerve conduction studies.

Officers and directors

Shai N. Gozani M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer, Secretary
Age: 50
Bio & Compensation  - Reuters
Thomas T. Higgins Chief Financial Officer, Senior Vice President, Treasurer
Age: 63
Bio & Compensation  - Reuters
Francis X. McGillin Senior Vice President, General Manager - Consumer Wearables
Age: 54
Bio & Compensation  - Reuters
David E. Goodman M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Allen J. Hinkle M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Nancy E. Katz Independent Director
Age: 55
Bio & Compensation  - Reuters
Timothy R. Surgenor Independent Director
Age: 55
Bio & Compensation  - Reuters
David Van Avermaete Independent Director
Age: 63
Bio & Compensation  - Reuters